Apollo Endosurgery Upgraded To Overweight From Neutral At Piper Sandler

Piper Sandler analyst Adam Maeder upgraded Apollo Endosurgery (APEN) to Overweight from Neutral with a price target of $5, up from $2.

The analyst likes the stock's risk/reward profile with the approval of a COVID-19 vaccine "becoming seemingly closer each day."

Procedure volumes both in Apollo's endoscopic suturing system and intragastric balloon franchise have bounced back better than expected, and the company has made good progress on key operational initiatives, Maeder tells investors in a research note.


Disclaimer: TheFly's news is intended for informational purposes only and does not claim to be actionable for investment decisions. Read more at  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.